Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,126 active trials259 approved drugs3,742 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,710 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03649529 | Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy | unknown | Early Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT03578432 | Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy | terminated | Early Phase 1 | 2 | University of ArizonaOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | withdrawn | Early Phase 1 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04169932 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01263613 | Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer | completed | Early Phase 1 | 6 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01753908 | Broccoli Sprout Extract in Treating Patients With Breast Cancer | completed | Early Phase 1 | 30 | Roswell Park Cancer InstituteOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT04130750 | Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice | unknown | Early Phase 1 | 200 | Peking University People's HospitalOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04113096 | Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer | unknown | Early Phase 1 | 104 | The University of The West IndiesOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT02316795 | Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma | completed | Early Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT04056026 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | completed | Early Phase 1 | 1 | ProgenaBiomeOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT01730729 | Cabergoline in Metastatic Breast Cancer | completed | Early Phase 1 | 20 | Northwestern UniversityOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03940001 | A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer | unknown | Early Phase 1 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02628080 | Atovaquone as Tumour HypOxia Modifier(ATOM) | completed | Early Phase 1 | 46 | University of OxfordOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04017845 | Screening for Colorectal Cancer in Average and High Risk Population | completed | Early Phase 1 | 537 | Lewai Sharki Abdulaziz, MSc PhDOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT04076137 | Targeted T-cell Therapy in Solid Tumors | unknown | Early Phase 1 | 10 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT01504126 | Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 29, 2019 | clinicaltrials |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | terminated | Early Phase 1 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01992705 | Borderline Pancreas Study: FOLFIRINOX +SBRT(GCC 1324) | completed | Early Phase 1 | 8 | University of Maryland, BaltimoreOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03116659 | CTCL Directed Therapy | unknown | Early Phase 1 | 8 | James J. Peters Veterans Affairs Medical CenterFED | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | unknown | Early Phase 1 | 27 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01722149 | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma | completed | Early Phase 1 | 4 | University of ZurichOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | unknown | Early Phase 1 | 75 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT04046185 | Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer(ECCT) | unknown | Early Phase 1 | 60 | Shanghai First Maternity and Infant HospitalOTHER | 0 | Aug 6, 2019 | clinicaltrials |
| NCT01789827 | Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy | completed | Early Phase 1 | 5 | Mayo ClinicOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01747798 | Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Early Phase 1 | 10 | Mayo ClinicOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT04041882 | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02806817 | ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism | completed | Early Phase 1 | 40 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00214422 | Intensity Modulated Radiation Therapy for Prostate Cancer | completed | Early Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03315065 | 19F Thoracic Radiotherapy for Lung Cancer | completed | Early Phase 1 | 6 | Hal C CharlesOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | terminated | Early Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT01138553 | Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer | terminated | Early Phase 1 | 4 | University of California, San DiegoOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT01660529 | Multi-peptide Vaccine With Basilixumab for Breast Cancer | completed | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02295956 | Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer | completed | Early Phase 1 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02729194 | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | completed | Early Phase 1 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | completed | Early Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jun 6, 2019 | clinicaltrials |
| NCT03960788 | Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer | unknown | Early Phase 1 | 50 | University of CincinnatiOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT02285738 | Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis | completed | Early Phase 1 | 17 | Case Comprehensive Cancer CenterOTHER | 1 | May 8, 2019 | clinicaltrials |
| NCT01276613 | Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas | terminated | Early Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | May 2, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 6, 2019source: clinicaltrials